Back
Mesa Laboratories 10K Form
Sell
47
MLAB
Mesa Laboratories
Last Price:
$86.53
Seasonality Move:
-2%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-02-05 | 10Q | MLAB/Mesa Laboratories Quarterly |
2023-11-06 | 10Q | MLAB/Mesa Laboratories Quarterly |
2023-08-03 | 10Q | MLAB/Mesa Laboratories Quarterly |
2023-02-06 | 10Q | MLAB/Mesa Laboratories Quarterly |
2022-11-03 | 10Q | MLAB/Mesa Laboratories Quarterly |
2022-08-04 | 10Q | MLAB/Mesa Laboratories Quarterly |
Receive MLAB News And Ratings
See the #1 stock for the next 7 days that we like better than MLAB
MLAB Financial Statistics
Sales & Book Value
Annual Sales: | $241M |
---|---|
Cash Flow: | $11.7M |
Price / Cash Flow: | 11.62 |
Annual Sales: | $29.30 |
Price / Book: | 3.08 |
Profitability
EPS (TTM): | -0.37000 |
---|---|
Net Income (TTM): | $-2M |
Gross Margin: | $150.9M |
Return on Equity: | -1.28% |
Return on Assets: | -0.45% |
Mesa Laboratories Earnings Forecast
Key Mesa Laboratories Financial Ratios
-
The Gross Profit Margin over the past 38 years for MLAB is 62.61%.
-
The Selling, General & Administrative Expenses for MLAB have been equal to 47.73% of Gross Profit Margin.
-
The Research & Development expenses have been 8.10% of Revenue.
-
The Net Earning history of MLAB is -0.82% of Total Revenues.
-
Per Share Earnings over the last 38 years have been positive in 27 years.
Mesa Laboratories Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Life Sciences Tools & Services |
Sector: | Health Care |
Current Symbol: | MLAB |
CUSIP: | 59064R |
Website: | mesalabs.com |
Debt
Debt-to-Equity Ratio: | 1.11 |
---|---|
Current Ratio: | 0.63 |
Quick Ratio: | 0.42 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 12.65 |
MLAB Technical Analysis vs Fundamental Analysis
Sell
47
Mesa Laboratories (MLAB)
is a Sell
Is Mesa Laboratories a Buy or a Sell?
-
Mesa Laboratories stock is rated a SellThe current Mesa Laboratories [MLAB] share price is $90.31. The Score for MLAB is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.